title: Imatinib dose escalation to achieve molecular responses in patients with chronic myeloid leukemia in late chronic phase.
authors.forename: F
authors.initials: F
authors.lastname: Stagno
authors.forename: P
authors.initials: P
authors.lastname: Vigneri
authors.forename: V
authors.initials: V
authors.lastname: Del Fabro
authors.forename: S
authors.initials: S
authors.lastname: Stella
authors.forename: M
authors.initials: M
authors.lastname: Massimino
authors.forename: S
authors.initials: S
authors.lastname: Berretta
authors.forename: A
authors.initials: A
authors.lastname: Messina
authors.forename: F
authors.initials: F
authors.lastname: Di Raimondo
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001549:Benzamides; D015331:Cohort Studies; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy*; D008297:Male; D010879:Piperazines / Q000008:administration & dosage / Q000627:therapeutic use*; D011743:Pyrimidines / Q000008:administration & dosage / Q000627:therapeutic use*
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate